In the wake of the Childhood and Adolescent Migraine Prevention (CHAMP) Study,1 many clinicians have been left wondering how best to treat children and adolescents who have frequent migraine. The CHAMP Study aimed to identify an optimal first-line migraine preventive treatment for those aged 8 to 17 years. After a 4-week baseline run-in period, participants were randomized in a 2:2:1 fashion to either amitriptyline (1 mg/kg/d), topiramate (2 mg/kg/d), or placebo. Both amitriptyline and topiramate are commonly used migraine preventives, and topiramate became US Food and Drug Administration labeled for migraine prevention in adolescents during the conduct of the CHAMP Study. In all 3 arms, approximately 60% of participants met the primary end point of a 50% or greater reduction in headache days at 24 weeks. Participants in the 2 medication arms had more adverse events than those in the placebo arm, worrying some that we might do more harm than good with our prescription pads. However, it would be a disservice to children and adolescents with migraine to conclude from the CHAMP Study that we as physicians have nothing to offer them.
Gelfand AA, Qubty W, Goadsby PJ. Pediatric Migraine Prevention—First, Do No Harm. JAMA Neurol. 2017;74(8):893–894. doi:10.1001/jamaneurol.2017.1011
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: